Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Effectiveness of lanthanum carbonate treatment used in combination with other phosphate binders in peritoneal dialysis patients.

Yamada S, Yoshida H, Taniguchi M, Tanaka S, Eriguchi M, Nakano T, Tsuruya K, Kitazono T.

Intern Med. 2012;51(16):2097-104. Epub 2012 Aug 15.

2.

Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis.

Shigematsu T; Lanthanum Carbonate Research Group..

Ther Apher Dial. 2008 Feb;12(1):55-61. doi: 10.1111/j.1744-9987.2007.00541.x.

PMID:
18257813
3.

Lanthanum carbonate for hyperphosphatemia in patients on peritoneal dialysis.

Ohno M, Ohashi H, Oda H, Yokoyama H, Okada M, Nagaya M, Izumi K, Ito H, Katoh S.

Perit Dial Int. 2013 May-Jun;33(3):297-303. doi: 10.3747/pdi.2012.00600. Epub 2012 Dec 3.

4.

One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis.

Shigematsu T; Lanthanum Carbonate Research Group..

Ther Apher Dial. 2010 Feb;14(1):12-9. doi: 10.1111/j.1744-9987.2009.00697.x.

PMID:
20438515
6.

Effect of lanthanum carbonate on phosphate control in continuous ambulatory peritoneal dialysis patients in Korea: a randomized prospective study.

Lee YK, Choi HY, Shin SK, Lee HY.

Clin Nephrol. 2013 Feb;79(2):136-42. doi: 10.5414/CN107362.

PMID:
23211335
8.

Safety and efficacy evaluation of lanthanum carbonate for hyperphosphatemia in end-stage renal disease patients.

Shigematsu T, Ohya M, Negi S, Masumoto AR, Nakashima YM, Iwatani Y, Moribata MK, Yamanaka S, Tatsuta K, Mima T.

Contrib Nephrol. 2015;185:42-55. doi: 10.1159/000380969. Epub 2015 May 19.

PMID:
26023014
9.

Multicenter study of long-term (two-year) efficacy of lanthanum carbonate.

Ando R, Kimura H, Sato H, Iwamoto S, Yoshizaki Y, Chida Y, Ishida Y, Takayama M, Yamada K, Tachibana K, Ohtsuka M, Kikuchi K, Inoue A.

Ther Apher Dial. 2013 Apr;17 Suppl 1:2-8. doi: 10.1111/1744-9987.12046.

PMID:
23586506
10.

Combined therapy with lanthanum carbonate and calcium carbonate for hyperphosphatemia decreases serum FGF-23 level independently of calcium and PTH (COLC Study).

Shigematsu T, Negi S; COLC Research Group..

Nephrol Dial Transplant. 2012 Mar;27(3):1050-4. doi: 10.1093/ndt/gfr388. Epub 2011 Jul 19.

PMID:
21771755
13.
14.

Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden.

Hutchison AJ, Laville M; SPD405-313 Lanthanum Study Group..

Nephrol Dial Transplant. 2008 Nov;23(11):3677-84. doi: 10.1093/ndt/gfn310. Epub 2008 Jun 24.

15.

Efficacy of continuous oral administration of lanthanum carbonate over 24 months.

Ishizu T, Hong Z, Matsunaga T, Kaneko Y, Taru Y.

Ther Apher Dial. 2013 Apr;17 Suppl 1:22-8. doi: 10.1111/1744-9987.12042.

PMID:
23586509
16.

Multicenter study on the long-term (3-year) efficacy of lanthanum carbonate in dialysis patients.

Ando R, Yama S, Ohnishi T, Iwamoto S, Kimura H, Chida Y, Ishida Y, Yamada K, Inagaki Y, Takayama M, Tachibana K, Kikuchi K, Inoue A, Ohtsuka M.

Ther Apher Dial. 2014 Jun;18 Suppl 1:2-8. doi: 10.1111/1744-9987.12206.

PMID:
24953759
17.

A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.

Prajapati VA, Galani VJ, Shah PR.

Saudi J Kidney Dis Transpl. 2014 May;25(3):530-8.

18.

The real-world dose-relativity of sevelamer hydrochloride and lanthanum carbonate monotherapy in patients with end-stage renal disease.

Wilson RJ, Keith MS, Preston P, Copley JB.

Adv Ther. 2013 Dec;30(12):1100-10. doi: 10.1007/s12325-013-0077-5. Epub 2013 Dec 5.

PMID:
24307220
19.

Study of prolonged administration of lanthanum carbonate in dialysis patients.

Gotoh J, Kukita K, Tsuchihashi S, Hattori M, Iida J, Horie T, Onodera K, Furui H, Tamaki T, Meguro J, Yonekawa M, Kawamura A.

Ther Apher Dial. 2013 Apr;17 Suppl 1:9-14. doi: 10.1111/1744-9987.12043.

PMID:
23586507
20.

Lanthanum carbonate is an effective hypophosphatemic agent for hemodialysis patients intolerant of other phosphate binders.

Chan WL, Rounsley K, Chapman E, Collings K, Dale C, De Waal S, Patel V, Tanner J, Turner E, Moore J, Borrows R.

J Ren Nutr. 2010 Jul;20(4):270-7. doi: 10.1053/j.jrn.2009.10.009. Epub 2010 Apr 2.

PMID:
20362463

Supplemental Content

Support Center